Literature DB >> 15738748

Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study.

Jonathan R T Davidson1, Kathryn M Connor, Michael A Hertzberg, Richard H Weisler, William H Wilson, Victoria M Payne.   

Abstract

The effect of fluoxetine (FLU) in posttraumatic stress disorder was studied in a one-year trial. Subjects received open-label treatment for 6 months, followed by double-blind randomized treatment with FLU or placebo (PBO) for 6 months. Rates of relapse were compared using the Clinical Global Impressions of Improvement. One hundred twenty-three subjects entered open-label treatment, of whom 114 returned at least once. Sixty-two subjects were randomized to receive FLU or PBO, of whom 57 returned at least once and were analyzed. The dose of FLU ranged from 10 to 60 mg/d; at randomization, mean doses were 48.6 and 42.1 mg for FLU and PBO groups. Rates of relapse were 22% for FLU versus 50% for PBO (P = 0.02), and time to relapse on FLU was longer than for PBO (P = 0.02, log-rank statistic). The odds ratio for relapse on PBO relative to FLU was 3.50. No significant differences were found on other measures. Fluoxetine was well tolerated during double-blind treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15738748     DOI: 10.1097/01.jcp.0000155817.21467.6c

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  13 in total

1.  Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment.

Authors:  Kathryn M Connor; Jonathan R T Davidson; Richard H Weisler; Wei Zhang; Kurian Abraham
Journal:  Psychopharmacology (Berl)       Date:  2005-12-10       Impact factor: 4.530

Review 2.  Post-traumatic stress disorder.

Authors:  Jonathan I Bisson
Journal:  BMJ Clin Evid       Date:  2010-02-03

3.  Management of Psychiatric Disorders in Patients with Stroke and Traumatic Brain Injury.

Authors:  Gautam Saha; Kaustav Chakraborty; Amrit Pattojoshi
Journal:  Indian J Psychiatry       Date:  2022-03-23       Impact factor: 2.983

Review 4.  Pharmacotherapy for post traumatic stress disorder (PTSD).

Authors:  Taryn Williams; Nicole J Phillips; Dan J Stein; Jonathan C Ipser
Journal:  Cochrane Database Syst Rev       Date:  2022-03-02

5.  Enhancing clinical trial design of interventions for posttraumatic stress disorder.

Authors:  Andrew C Leon; Lori L Davis
Journal:  J Trauma Stress       Date:  2009-12

Review 6.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 7.  Pharmacotherapy in post-traumatic stress disorder: evidence from randomized controlled trials.

Authors:  Gregory M Sullivan; Yuval Neria
Journal:  Curr Opin Investig Drugs       Date:  2009-01

8.  Pharmacotherapy of PTSD: Current Status and Controversies.

Authors:  Gregory M Sullivan; Yuval Neria
Journal:  Psychiatr Ann       Date:  2009-06

9.  Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.

Authors:  Ellen Van Leeuwen; Mieke L van Driel; Mark A Horowitz; Tony Kendrick; Maria Donald; An Im De Sutter; Lindsay Robertson; Thierry Christiaens
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

Review 10.  PTSD and comorbid AUD: a review of pharmacological and alternative treatment options.

Authors:  Elizabeth Ralevski; Lening A Olivera-Figueroa; Ismene Petrakis
Journal:  Subst Abuse Rehabil       Date:  2014-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.